TScan Therapeutics
Boston, US · Founded 2018 · 7 known investors
TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer patients. Its pipeline focuses on hematologic malignancies, advancing engineered T-cell therapy candidates from discovery through clinical development.
BiotechHealthtechMedical Devices
Founders & leadership
DS
David SouthwellExecutive
RC
Robert CraneExecutive
Board
LH
SK
CM
Campbell MurrayBoard director
HS
CW
TB
Timothy BarberichBoard director
Investors · 7
Astellas Venture Management LLCSouth San Francisco · $200K – $5M
Bessemer Venture PartnersRedwood City · $5M – $100M
Longwood FundBoston
RA CapitalBoston
6 Dimensions CapitalreportedGrand Caymanvia Hannes Smarason · board
Longwood Special SituationsreportedBoston
PitangoreportedTel Aviv · $4M – $100Mvia Ittai Harel · board
Reported raises · per SEC filings
Form D private placements$123.3M disclosed across 2 rounds · 2019–2021
▶$100MraisedJan 2021 · 16 investors · BiotechnologyRule 506(b)
▶$100MraisedJan 2021 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ittai HarelDirector
- Nandita ShangariDirector
- Christoph WestphalDirector
- Brian SilverDirector
- Doug FambroughDirector
- Timothy BarberichDirector
- David SouthwellExecutive Officer, Director
- Andrew HedinDirector
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$23.3MraisedJul 2019 · 9 investors · BiotechnologyRule 506(b)
▶$23.3MraisedJul 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lea HachigianDirector
- David SouthwellExecutive Officer, Director
- Steve KrausDirector
- Campbell MurrayDirector
- Hannes SmarasonDirector
- Christoph WestphalDirector
- Robert CraneExecutive Officer
- Timothy BarberichDirector
- Offering amount
- $23.3M
- Amount sold
- $23.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood33 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha27 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
Stocktwits26 shared keywordsStocktwits is a social platform for investors and traders to share market news, discussions, sentiment polls, and live financial content. It aggregates breaking market news, equity coverage, and community discussions around individual stocks and crypto.
Solu25 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Companies competing with TScan Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TScan Therapeutics do?
- TScan Therapeutics is a clinical-stage biotechnology company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer patients. Its pipeline focuses on hematologic malignancies, advancing engineered T-cell therapy candidates from discovery through clinical development.
- Who are TScan Therapeutics's investors?
- TScan Therapeutics's investors include Astellas Venture Management LLC, Bessemer Venture Partners, Longwood Fund, RA Capital, 6 Dimensions Capital, Longwood Special Situations, Pitango.
- How much funding has TScan Therapeutics raised?
- TScan Therapeutics has disclosed $123.3M raised across 2 rounds.
- Where is TScan Therapeutics headquartered?
- TScan Therapeutics is headquartered in Boston, US.